The potential effects of ceramide and dihydroceramide on CFTR activity are relevant to many inflammatory lung diseases, and to CF in particular (Chakinala et al., 2019; Devlin et al., 2011; Ghidoni et al., 2015). This evidence concerns the gene CFTR and cystic fibrosis.